Big pharma is bad at managing cash and Pfizer's the worst
This article was originally published in Scrip
Executive Summary
There is much room for improvement by big pharma firms in their management of working capital, according to a new report by bankers Citi, which points out that the industry is missing some obvious tricks, such as paying out its bills far sooner than it receives cash from others.